期刊文献+

报告基因法测定人干扰素γ药物的生物学活性

A Reporter Gene Assay for Determination of Biological Activity of InterferonγDrugs
原文传递
导出
摘要 目的建立一种用于人干扰素γ药物生物学活性测定的报告基因法,以提高人干扰素γ药物生物学活性测定的生物安全性、简便性和精密度。方法构建含有人干扰素γ反应性DNA元件和报告基因的转基因细胞,建立使用该细胞测定人干扰素γ药物生物学活性的报告基因法,进行方法学验证,评价其与细胞病变抑制法测定结果的一致性。结果构建了含有干扰素γ活化位点和荧光素酶报告基因的转基因HeLa细胞,建立了人干扰素γ药物生物学活性的测定方法,该方法的剂量反应曲线符合四参数Logistic曲线,具有良好的专属性,3批样品的加标回收率在80%~120%之间,试验内变异系数小于8%,试验间变异系数小于11%,操作人员间变异系数小于15%,细胞代次、细胞接种密度和药物作用时间等试验条件的变化对测定结果无显著影响,该方法与病毒抑制法的测定结果之间有很高的一致性。结论建立的报告基因法不需要使用病毒,操作简便,具有良好的专属性、准确度、精密度、耐用性,可作为病毒抑制法的替代方法,用于人干扰素γ药物生物学活性测定。 OBJECTIVE To establish a reporter gene assay for the determination of biological activity of human interferonγdrugs,in order to improve the biosafety,simplicity and precision of the determination of biological activity.METHODS Transgenic cells containing human interferonγreactive DNA elements and a reporter gene were constructed,a reporter gene assay was established based on the cells to determine the biological activity of human interferonγdrugs,methodological verification was conducted,and its consistency with the results of cytopathic effect inhibition assay was evaluated.RESULTS HeLa transgenic cells containingγinterferon activation site and a luciferase reporter gene were constructed,and a assay for determining the biological activity of human interferonγwas established.The dose-response curve of the assay conformed to the four parameter logistic curve,and the assay had good specificity.The recovery rate of the three batches of samples was between 80%and 120%.The coefficient of variation(CV)within the test was less than 8%,the CV value between the tests was less than 11%,and the CV value between the operators was less than 15%.Changes in test conditions such as cell generation,inoculation density and drug action time had no significant effect on the determination results.There was a high consistency between the determination results of this assay and cytopathic effect inhibition assay.CONCLUSION The established reporter gene assay does not require the use of viruses,is easy to operate,has good specificity,accuracy,precision,and durability.It can be used as an alternative assay to cytopathic effect inhibition assay for the determination of the biological activity of human interferonγdrugs.
作者 裴德宁 秦玺 于传飞 郭莹 李响 于雷 周勇 PEI Dening;QIN Xi;YU Chuanfei;GUO Ying;LI Xiang;YU Lei;ZHOU Yong(National Institutes for Food and Drug Control,Beijing 100050,China)
出处 《中国药学杂志》 CAS CSCD 北大核心 2023年第24期2240-2245,共6页 Chinese Pharmaceutical Journal
基金 国家质量基础设施项目资助(2021YFF0600804)。
关键词 干扰素Γ 生物学活性 转基因细胞 报告基因法 方法学验证 interferon biological activity transgenic cell reporter gene assay methodological verification
  • 相关文献

参考文献2

二级参考文献28

  • 1袁力勇,饶春明,郭莹,李响,刘长暖,张翊,王军志.重组人纽兰格林生物学活性检测方法及质控标准[J].中国生物制品学杂志,2004,17(6):374-376. 被引量:5
  • 2谭兴容,王毅,杨刚毅.Exendin-4与糖尿病治疗[J].重庆医学,2006,35(10):904-906. 被引量:8
  • 3李克坚,梁成罡,杨勇,张慧,杨化新.重组促胰岛素分泌素生物学活性测定方法的研究[J].药物分析杂志,2006,26(12):1691-1693. 被引量:4
  • 4RAVASSA S, ZUDAIRE A, DIEZ J. GLP-1 and cardioprotection: from bench to bedside[J]. Cardivasc Res, 2012, 94 ( 2 ): 316.
  • 5DING X, SAXENA NK, LIN S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1)receptor agonist, reverses hepatic steatosis in ob/ob mice [ J ]. Hepatology, 2006,43 ( 1 ): 173.
  • 6TRUJILLO JM, NUFFER W, ELLIS SL. GLP-1 receptor agonists: a review of head-to-head clinical studies [ J ]. Ther Adv Endocrinol Metab, 2015,6( 1 ): 19.
  • 7NOVAK B, METELKO Z. Liraglutide in the treatment of diabetes type 2 [ J ]. Lijec Vjesn, 2011,133 ( 7-8 ): 269.
  • 8GALLWITZ B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents [J]. Drugs, 2011, 71 ( 13 ): 1675.
  • 9无锡和邦生物科技有限公司,江苏省血吸虫病防治研究所.一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法:中国,200810018639[P].2008—03—04.
  • 10王兰,范文红,丁有学,等.注射用促胰岛素分泌肽融合蛋白质控方法和质量标准研究[C]//2011中国生物制品年会论文集.北京:中华预防医学会,2011.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部